- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03437473
Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
A Randomized Controlled Study of the Safety and Efficacy of Neurostimulation Using a Vagus Nerve Stimulation Device in Patients With Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a two-stage study where Stage 1 is open label, and Stage 2 is randomized and sham controlled where the sites and subjects are blinded to treatment. Three subjects will be enrolled in Stage 1 of the study. And 12 subjects will be enrolled in Stage 2. Subjects will be treated for a total of 12 weeks.
Subjects will be asked to visit the clinic at day 0, week 1-6, week 8 and week 12. During these visits, the following activities will be conducted: standard patient and physician assessments of RA activity, blood sample collection for RA biomarkers, and a hand MRI.
Subjects who complete the study will have the option to enroll in a long-term extension study. Subjects that do not participate in the extension study can opt to either have their device permanently inactivated and left in place or have the device surgically explanted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Aventura, Florida, United States, 33180
- Arthritis & Rheumatic Disease Specialties
-
Zephyrhills, Florida, United States, 33542
- Florida Medical Clinic, P.A.
-
-
New York
-
Great Neck, New York, United States, 11021
- Northwell Health Division of Rheumatology
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female and 22-75 years of age, inclusive
- Have provided informed consent
- Have a diagnosis of adult-onset rheumatoid arthritis as defined by the 2010 ACR/EULAR classification criteria (Aletaha, 2010)
- Have moderately to severely active RA defined by at least 4/28 tender and 4/28 swollen joints and CDAI score >10
Have been treated at approved doses with at least 2 biologic DMARDs and/or new targeted synthetic DMARDs (e.g. JAK inhibition) for at least 3 months and either:
- experienced insufficient efficacy or loss of efficacy
- experienced intolerance of such treatment
- Have had regular use of at least 1 conventional DMARDs for at least the 12 weeks prior to study entry with a continuous, non-changing dose for at least 8 weeks prior to screening visit
- Women of childbearing potential must not be pregnant at the time of screening and must agree to use a double barrier method of contraception throughout the study
Exclusion Criteria:
Have taken the following within the defined time period prior to screening visit:
i. Rituximab: 6 months ii. Infliximab, golimumab, adalimumab, certolizumab pegol, tocilizumab: 60 days iii. Abatacept, etanercept, anakinra: 30 days iv. Tofacitinib: 30 days v. Investigational biologic agents: 6 months for depleting agents, 60 days for others vi. Investigational small molecules: 5 times the pharmacokinetic half-life or 30 days, whichever is longer vii. Intra-articular corticosteroid injection: 30 days
- Are currently receiving corticosteroids at doses greater than 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of screening visit
- Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of screening visit
- Documented significant psychiatric illness or substance abuse
- Active infection requiring treatment with antibiotics
- Uncontrolled hypertension
- Uncontrolled diabetes
- History of stroke
- Known cardiac disease, including cardiomyopathy with ejection fraction <40%, recent myocardial infarction or unstable angina, or heart failure with New York Heart Association class III or IV symptoms
- Known neurological syndromes
- Known atherosclerotic disease including contralateral carotid artery
- BMI <18.5 or >35
- Any condition per the investigator's clinical judgment that precludes participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active stimulation QD
|
Active Implantable Vagus Nerve Stimulation device.
Other Names:
|
Active Comparator: Active stimulation QID
|
Active Implantable Vagus Nerve Stimulation device.
Other Names:
|
Sham Comparator: No stimulation
|
Active Implantable Vagus Nerve Stimulation device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of Adverse Events
Time Frame: Enrollment to Week 12
|
treatment-emergent incidence rates of Adverse Events, Adverse Device Effects, Serious Adverse Events, Serious Adverse Device Effects, Unanticipated Adverse Device Effects, and Unanticipated Serious Adverse Device Effects
|
Enrollment to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in Disease Activity Score (DAS) 28 - C-reactive protein (CRP)
Time Frame: change from baseline at Day 0 and Week 12
|
comparison between the active device group and the inactive device group of the change in DAS28-CRP
|
change from baseline at Day 0 and Week 12
|
change in American College of Rheumatology (ACR) 20, 50 and 70 response rates
Time Frame: change from baseline at Day 0 and Week 12
|
comparison between the active device group and the inactive device group of the change in ACR 20/50/70
|
change from baseline at Day 0 and Week 12
|
change in European League Against Rheumatism (EULAR) response and remission rate
Time Frame: change from baseline at Day 0 and Week 12
|
comparison between the active device group and the inactive device group of the change in EULAR
|
change from baseline at Day 0 and Week 12
|
change in hand MRI
Time Frame: change from baseline at Day 0 and Week 12
|
comparison between the active device group and the inactive device group of the change in Outcomes Measures in Rheumatology Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS) hand MRI index of synovitis
|
change from baseline at Day 0 and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mark Genovese, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Cholinergic Agents
Other Study ID Numbers
- SPM-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
-
SetPoint Medical CorporationActive, not recruitingRheumatoid ArthritisUnited States
-
Centre Hospitalier Universitaire de Saint EtienneNational Cancer Institute, FranceCompletedCancer | Sequels | ComplicationsFrance
-
Xuanwu Hospital, BeijingNational Key Research and Development Project, ChinaRecruitingStroke, Ischemic | Intracranial AtherosclerosisChina
-
Saint-Joseph UniversityUnknown
-
Assistance Publique - Hôpitaux de ParisTerminatedHeart-lung Transplant RejectionFrance
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
Vastra Gotaland RegionGöteborg UniversityRecruitingTakotsubo SyndromeNorway, Denmark, Sweden
-
Mayo ClinicCompleted
-
University Medical Center GroningenBoehringer IngelheimRecruiting
-
Chiesi Farmaceutici S.p.A.CompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom